Compare Adaptive Biotechnologies Corp (ADPT) vs Blackrock Inc (BLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Blackrock Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Blackrock Inc trades at $986.39 (market cap $156.46B). The key difference: Blackrock Inc is far larger — about 47× Adaptive Biotechnologies Corp's market cap, and Blackrock Inc pays a 2.27% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BLK | |
|---|---|---|
Market Cap | $3.33B | $156.46B |
Sector | Health | Financials |
52-Week High | $22.37 | $1.20K |
52-Week Low | $10.24 | $922.90 |
Enterprise Value | $3.19B | $158.28B |
Volume | — | 641,547 |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BlackRock (BLK) trades at $1,009.43, up 1.38% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $12.53 exceeding expectations. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights expansion into Nasdaq-100 ETFs and Bitcoin ETF offerings, positioning for growth in private markets and AI-driven demand.
Outlook remains positive with a consensus price target of $1,260, reflecting 25% upside. Key risks include volatile cash flows and competitive pressures in ETF markets. Institutional sentiment is strongly bullish, with 76% of analysts rating Buy. Earnings on July 15 will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
